stoxline Quote Chart Rank Option Currency Glossary
  
Lipella Pharmaceuticals Inc. (LIPO)
0.44  -0.005 (-1.21%)    07-23 16:00
Open: 0.46
High: 0.4675
Volume: 60,207
  
Pre. Close: 0.4454
Low: 0.43
Market Cap: 3(M)
Technical analysis
2024-07-23 4:53:31 PM
Short term     
Mid term     
Targets 6-month :  0.66 1-year :  0.78
Resists First :  0.56 Second :  0.67
Pivot price 0.45
Supports First :  0.4 Second :  0.33
MAs MA(5) :  0.45 MA(20) :  0.46
MA(100) :  0.66 MA(250) :  1.09
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  22.2 D(3) :  27.4
RSI RSI(14): 36.5
52-week High :  2.71 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LIPO ] has closed above bottom band by 30.4%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.47 - 0.47 0.47 - 0.47
Low: 0.42 - 0.43 0.43 - 0.43
Close: 0.43 - 0.44 0.44 - 0.44
Company Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Headline News

Fri, 24 May 2024
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 - InvestorPlace

Tue, 21 May 2024
Following Guidance from U.S. Food & Drug Administration in - GlobeNewswire

Thu, 16 May 2024
Clearside Biomedical And 3 Other Penny Stocks Insiders Are Buying - Benzinga

Tue, 02 Apr 2024
symbol__ Stock Quote Price and Forecast - CNN

Fri, 10 Nov 2023
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease - PR Newswire

Wed, 25 Oct 2023
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 8 (M)
Shares Float 5 (M)
Held by Insiders 36.7 (%)
Held by Institutions 4.9 (%)
Shares Short 16 (K)
Shares Short P.Month 22 (K)
Stock Financials
EPS -0.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.36
Profit Margin 0 %
Operating Margin -834.7 %
Return on Assets (ttm) -78.7 %
Return on Equity (ttm) -148.8 %
Qtrly Rev. Growth 23.6 %
Gross Profit (p.s.) 0
Sales Per Share 0.06
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -0.6
PEG Ratio 0
Price to Book value 1.22
Price to Sales 7.01
Price to Cash Flow -0.97
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android